Kevin Johnson, PhD, MBA
Chief Regulatory Officer
Kevin joined Ring Therapeutics as Chief Regulatory Officer in September 2021. He has over 28 years of experience in the implementation of global regulatory and development strategies for a variety of drugs, biologics, combination products, and cell/gene therapies. He has led global project teams in early, mid- and late-stage development programs across a variety of therapeutic areas and directed the preparation and maintenance of INDs, CTAs, BLAs, NDAs, and MAAs. Kevin’s most recent role was Senior Vice President at Inozyme Pharma, leading global strategy and tactics for regulatory, quality, and product development activities. Prior to Inozyme, Kevin held several positions of increasing responsibility for regulatory and quality activities at Imara Inc., Sucampo Pharmaceuticals, and Vtesse Inc. He also served as Director, Global Regulatory Affairs for Rare Diseases and Gene Therapies at GlaxoSmithKline (GSK). Kevin earned a PhD in Neurobiology from the University of North Carolina (UNC) School of Medicine, an MBA from the Kenan-Flagler School of Business at UNC, and a BS in Chemistry from the University of South Florida.